Literature DB >> 7636965

Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice.

J F Moffat1, M D Stein, H Kaneshima, A M Arvin.   

Abstract

To investigate the cell tropism and pathogenicity of varicella-zoster virus (VZV) strains, we analyzed VZV replication by using SCID-hu mice that carry human fetal thymus/liver implants under the kidney capsule or as subcutaneous fetal skin implants. MRC-5 cells infected with wild-type VZV or the Oka strain, used in the live attenuated varicella vaccine, were injected into the implants. The implants were surgically removed 2, 7, 14, and 21 days postinfection. The VZV titer from infected thymus/liver implants peaked on day 7 for the wild-type strain and on day 14 for the Oka strain. Histological analysis showed necrotic areas characterized by thymocyte depletion and fibrosis. VZV protein synthesis was detectable by immunohistochemical staining in the necrotic areas and in distant regions that did not show cytopathic changes, and VZV DNA was detected by in situ hybridization in the same distribution. Fluorescence-activated cell sorting analysis of thymocytes harvested at day 7 postinfection showed that VZV proteins were expressed in CD4+, CD8+, and CD4+ CD8+ T cells; VZV was cultured from each T-cell subpopulation. The Oka strain had tropism for human cell types similar to that of wild-type VZV. T lymphocytes released infectious VZV, which is a novel and important observation about the replication of this otherwise highly cell associated virus. VZV-infected skin implants exhibited microscopic epidermal lesions that were indistinguishable histologically from the characteristic lesions of varicella. These experiments demonstrate a unique tropism of VZV for human T lymphocytes, explaining its capacity to cause viremia in natural disease, and demonstrate the value of the SCID-hu model for studies of VZV pathogenesis.

Entities:  

Mesh:

Year:  1995        PMID: 7636965      PMCID: PMC189355     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Varicella-zoster virus infection of human mononuclear cells.

Authors:  D H Gilden; A R Hayward; J Krupp; M Hunter-Laszlo; J C Huff; A Vafai
Journal:  Virus Res       Date:  1987-04       Impact factor: 3.303

2.  Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization.

Authors:  C M Koropchak; S M Solem; P S Diaz; A M Arvin
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus.

Authors:  K Takahashi; S Sonoda; K Higashi; T Kondo; H Takahashi; M Takahashi; K Yamanishi
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Varicella in hairless guinea pigs.

Authors:  M G Myers; B L Connelly; L R Stanberry
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella.

Authors:  M H Sawyer; Y N Wu; C J Chamberlin; C Burgos; S K Brodine; W A Bowler; A LaRocco; E C Oldfield; M R Wallace
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

Review 6.  Varicella vaccine: the American experience.

Authors:  A A Gershon; P LaRussa; I Hardy; S Steinberg; S Silverstein
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

7.  Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella.

Authors:  C M Koropchak; G Graham; J Palmer; M Winsberg; S F Ting; M Wallace; C G Prober; A M Arvin
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

8.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

10.  Long-term human hematopoiesis in the SCID-hu mouse.

Authors:  R Namikawa; K N Weilbaecher; H Kaneshima; E J Yee; J M McCune
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  117 in total

1.  Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model.

Authors:  Takahiro Niizuma; Leigh Zerboni; Marvin H Sommer; Hideki Ito; Stewart Hinchliffe; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Identification and functional characterization of the Varicella zoster virus ORF11 gene product.

Authors:  Xibing Che; Stefan L Oliver; Marvin H Sommer; Jaya Rajamani; Mike Reichelt; Ann M Arvin
Journal:  Virology       Date:  2011-01-26       Impact factor: 3.616

3.  Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection and Reactivation.

Authors:  Sravya Kurapati; Tomohiko Sadaoka; Labchan Rajbhandari; Balaji Jagdish; Priya Shukla; Mir A Ali; Yong Jun Kim; Gabsang Lee; Jeffrey I Cohen; Arun Venkatesan
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

4.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo.

Authors:  Anne Schaap-Nutt; Marvin Sommer; Xibing Che; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

6.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis.

Authors:  Stefan L Oliver; Jennifer J Brady; Marvin H Sommer; Mike Reichelt; Phillip Sung; Helen M Blau; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-15       Impact factor: 11.205

8.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Replication of varicella-zoster virus in human skin organ culture.

Authors:  Shannon L Taylor; Jennifer F Moffat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 10.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.